|
Product Details:
Payment & Shipping Terms:
|
Name: | Lovastatin | Cas: | 75330-75-5 |
---|---|---|---|
Mf: | C24H36O5 | Purity: | 99% |
Appearance: | White Powder | Package: | 1kg/bag Or 25kgs/drum |
High Light: | Lovastatin CAS 75330-75-5,Reducing Cholesterol API Raw Powder,Lovastatin Chemical Product |
Good Quality Lovastatin CAS 75330-75-5 for Reducing Cholesterol Health Care API Raw Powder
Product Name | Lovastatin |
Alias | Mevinolin, 6-alpha-Methylcompactin;Mevinolin, Monacolin K, L 154803, MB 530B, MSD 803;Lovastatin (Mevacor); |
CAS No | 75330-75-5 |
MF | C24H36O5 |
MW | 404.54 |
EINECS | 1308068-626-2 |
Purity | 99% |
Appearance | White powder |
Melting Point | 175°C |
Standard | Enterprise Standard |
Usage | An antihypercholesterolemic agent. |
Description:
Lovastatin is a hexahydro naphthalene ester isolated from Aspergillus terreus broth. It is an inactive lactone only yielding activity upon hydrolysis after oral administration. It has a strong competitive inhibition on the HMG-CoA reductase in the liver. HMG-CoA reductase is rate-limiting enzyme for de novo cholesterol synthesis in vivo. The inhibition of the enzyme can block the conversion of HMG-CoA to methacrylic acid, causing significant reduction in cholesterol synthesis, and leading to increased expression of the liver LDL receptor which promotes the plasma LDL-C clearance.
The reduction of cholesterol synthesis can also cause reduced synthesis of liver ApoB100, thus causing that reduction of VLDL synthesis. Clinical observations show that it has a good effect of lowering of plasma total cholesterol and LDLC on hypercholesterolemia caused by various kinds of reasons such as heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia, and diabetes or kidney disease syndrome.
Lovastatin (mevinolin) is a metabolite first isolated from Monascus ruber and later found in several other fungal species. Lovastatin is a potent inhibitor of HMG-CoA. HMG-CoA reductase is the rate-controlling enzyme of the mevalonate pathway, responsible for the biosynthesis of cholesterol. Lovastatin was developed as a drug as a hypolipemic agent.
An antihypercholesterolemic agent. A fungal metabolite,which is a potent inhibitor of HMG-CoA reductase.
Use:
1. It is as a novel lipid regulating drugs-The inhibitor of HMG-CoA (β-hydroxy, β-methyl-glutaryl coenzyme A) reductase. It can significantly reduced serum total cholesterol level. After oral administration, it is hydrolyzed into corresponding β-hydroxy acid by 3-hydroxy-3-methylglutaryl coenzyme A reductase, and thus inhibiting the cholesterol biosynthesis. It is clinically used for treating heterozygous familial hypercholesterolemia, severe or mild hypercholesterolemia and light. It can also as an ancillary drug of dietary treatment for reducing the levels of excessively cholesterol and low-density protein cholesterol.
2. It is a cardiovascular systematic drug which can prevent the development of atherosclerosis and reduce the risk of myocardial infarction.
3. It is used for treating heterozygous familial and non familial, secondary hyperlipidemia, namely diabetes and nephrotic syndrome secondary hypercholesterolemia. It can reduce the level of TC, LF, LDL-C, and increase the level of HDL-C, reduce the risk of myocardial infarction, unstable angina and the necessity for percutaneous transluminal coronary angioplasty (PTCA).
Adenosine | AR | 58-61-7 | ≥99% |
Uridine | UR | 58-96-8 | ≥99% |
Cytidine | CR | 65-46-3 | ≥99% |
Xanthosine 5-monophosphate disodium salt | XMP- Na2 | 25899-70-1 | ≥98% |
Inosine-5'-monophosphate disodium salt octahydrate | IMP- Na2 | 20813-76-7 | ≥98% |
Adenosine 5′-monophosphate disodium salt | AMP- Na2 | 4578-31-8 | ≥98% |
Adenosine 5'-Monophosphatesodiumsalt | AMP- Na | .13474-03-8 | ≥98% |
5-Adenylic acid | AMP | 61-19-8 | ≥98% |
Adenosine 3',5'-cyclic monophosphate | Cyclic AMP,CAMP | 60-92-4 | ≥97% |
Uridine 5-monophosphate, disodium salt | UMP- Na2 | 3387-36-8 | ≥98% |
Uridine 5'-monophosphate | UMP | 58-97-9 | ≥98% |
Cytidine 5''-monophosphate disodium salt | CMP- Na2 | .6757-06-8 | ≥98% |
Cytidine 5′-monophosphate | CMP | 63-37-6 | ≥98% |
Citicoline sodium | CDPC-Na | 33818-15-4 | ≥98% |
uridine 5'-diphosphate disodium salt | UDP-Na2 | 27821-45-0 | ≥95% |
IDP-K2 | ≥90% | ||
Inosine-5'-diphosphoric acid disodium salt | IDP-Na2 | 54735-61-4 | ≥90% |
Cytidine 5'-Diphosphate Trisodium Salt Hydrate | CDP-Na3 | 34393-59-4 | ≥90% |
Cytidine-5'-diphosphate disodium salt | CDP-Na2 | 54394-90-0 | ≥90% |
Adenosine 5'-diphosphate dipotassiuM salt | ADP-K2 | 114702-55-5 | ≥95% |
Adenosine-5'-diphosphate, MonopotassiuM salt | ADP-K | 72696-48-1 | ≥95% |
Adenosine-5-diphosphate disodium salt | ADP-Na2 | 16178-48-6 | ≥95% |
Adenosine 5''-diphosphate sodium salt | ADP-Na | 20398-34-9 | ≥95% |
Adenosine 5''-diphosphate | ADP | 58-64-0 | ≥95% |
Uridine 5'-triphosphate disodium salt | UTP-Na3 | 19817-92-6 | ≥90% |
Uridine-5'-triphosphoric acid trisodium salt | UTP-Na2 | 285978-18-9 | ≥90% |
CTP-Na3 | ≥95% | ||
Cytidine 5′-triphosphate disodium salt | CTP-Na2 | 36051-68-0 | ≥95% |
Adenosine 5'-triphosphate disodium salt | ATP-Na2 | 987-65-5 | ≥95% |
Adenosin-5'-triphosphat | ATP | 56-65-5 |
Contact Person: July
Tel: 25838890